At a glance
| Primary receptor | Vasopressin V2 |
|---|---|
| Water-balance use | Central diabetes insipidus |
| Selected bleeding uses | Mild hemophilia A and type 1 von Willebrand disease |
| Major risk | Water intoxication and hyponatremia |
| Formulation caution | Indications and absorption differ by route |
Overview
Desmopressin has two major clinical roles that arise from V2-related biology. It replaces deficient antidiuretic activity in central diabetes insipidus and, in selected patients, helps hemostasis by increasing endogenous factor VIII and von Willebrand factor availability. Oral, injectable, nasal, and sublingual products have different strengths, absorption, and approved uses. Some formulations address nocturnal enuresis or nocturia, while those indications should not be assigned automatically to an injection or any nasal product. Patient selection matters in bleeding disorders because response varies and some disease subtypes can be harmed. The prominent hyponatremia warning is particularly important because water retention can progress to seizures or death.
How it works
Desmopressin preferentially stimulates vasopressin V2 receptors, increasing kidney water reabsorption and reducing urine volume. It also promotes release of stored hemostatic proteins, raising factor VIII activity and von Willebrand factor in responsive patients. Structural changes from native vasopressin prolong antidiuretic action and reduce vasopressor activity. A useful response therefore depends on both the disease mechanism and the availability of releasable clotting-factor stores.
Which conditions are covered by the injection?
DDAVP injection is labeled for central diabetes insipidus and specified hemophilia A and type 1 von Willebrand disease patients with adequate baseline factor VIII activity. Its hemostatic role concerns responsive patients and defined procedures or bleeding episodes. Nephrogenic diabetes insipidus and all von Willebrand subtypes should not be grouped into the same indication.
Supporting sources [1]
Oral indications are a separate product question
DDAVP tablets have labeling for central diabetes insipidus and primary nocturnal enuresis. Other desmopressin products have their own indications and restrictions. Route changes alter exposure, so the same numerical amount or an assumed conversion cannot be transferred between tablets, sprays, sublingual products, and injections.
Supporting sources [2]
Hyponatremia can be severe
The injection label carries a boxed warning for hyponatremia. Risk is affected by kidney function, fluid intake, sodium history, concurrent medicines, and illnesses that disturb fluid balance. Heart failure and uncontrolled hypertension are important contraindications in that label. Hypersensitivity and blood-pressure changes are additional concerns.
Supporting sources [1]
Can it be used for every von Willebrand disorder?
No. The injection’s indication is limited to selected type 1 disease, while type 2B disease can develop platelet aggregation, thrombocytopenia, or thrombosis. A measured response and the specific diagnosis matter. Increasing stored factors also differs from replacing missing factors with a concentrate.
Supporting sources [1]
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Modified nine-amino-acid vasopressin analog.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DDAVP injection — US prescribing information ↗Regulatory source · Checked 2026-10-27
- DDAVP tablets — US prescribing information ↗Regulatory source · Checked 2026-10-27